Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Value of Yosprala
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by goldbug83on Sep 15, 2016 7:14pm
95 Views
Post# 25242776

RE:Value of Yosprala

RE:Value of YospralaJason Napodano has followed POZEN and Aralez for a long time now and he conservatively forecasted annual sales in the $300-$400mil range even if they grab just a small portion of the asprin market. I would like to sell this stock in the $15-$20(CAN$) range if they hit their numbers and acquire some more drugs to add to the portfolio. Adams has a history of building Pharma companies quick then getting bought out. 

Sales force starts in October with 110 reps and hopefully they can string 2-3 quarters of big sales growth and we'll see this stock really gain some traction.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities